Insulin Degludec

BreastfeedingGeriatricPediatric
  • TRADE NAMES: Ryzodeg (Novo Nordisk); Tresiba (Novo Nordisk); Xultophy (Novo Nordisk)
  • INDICATIONS: Diabetes mellitus
  • CLASS: Human insulin analog, long-acting
  • HALF-LIFE: 25 hours

FDA APPROVAL DATE: 07/25/2015

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

ACE inhibitors, Albuterol, Alcohol, Angiotensin II receptor blocking agents, Beta blockers, Clonidine, Clozapine, Corticosteroids, Danazol, DDP-4-inhibitors, Disopyramide, Diuretics, Epinephrine, Estrogens, Fibrates, Fluoxetine, GLP-1 receptor agonists, Glucagon, Guanethidine, Isoniazid, Lithium, MAO inhibitors, Niacin, Octreotide, Olanzapine, Oral Contraceptives, Pentamidine, Pentoxifylline, Phenothiazines, Pramlintide, Propoxyphene, Protease inhibitors, Reserpine, Salicylates, SGLT-2 inhibitors, Somatropin, Sulfonamide antibiotics, Terbutaline, Thyroid hormones

PREGNANCY CATEGORY: C

NOTE

Contra-indicated during episodes of hypoglycemia.

Ryzodeg is insulin degludec and insulin aspart; Xultophy is insulin degludec and liraglutide; various forms of insulin are available - see other insulin profiles for reaction details.

Our database has 27 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
LOCAL.
OCULAR.
RESPIRATORY.
OTHER.


Page last updated 08/01/2022

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top